N. Colombo

Publications605
h-index72
Citations23,491
Highly Influential Citations623
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • I. Vergote
  • 1,210 Publications • 45,693 Citations
  • G. Scambia
  • 2,180 Publications • 49,978 Citations
  • A. Oza
  • 764 Publications • 30,033 Citations
  • D. Lorusso
  • 493 Publications • 11,139 Citations
  • Publications
  • Influence
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up.
TLDR
Results of this consensus conference on endometrial cancer, together with a summary of evidence supporting each recommendation, are detailed in this article.
Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
TLDR
Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up N. Colombo, C. Marini & C. Sessa .
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.
TLDR
Paclitaxel plus platinum chemotherapy seems to improve survival and progression-free survival among patients with relapsed platinum-sensitive ovarian cancer compared with conventional platinum-based chemotherapy.
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up N. Colombo, M. Peiretti, G. Parma, M. Lapresa, R. Mancari, S.…
Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
TLDR
Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up N. Colombo, C. Marini & C. Sessa .
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer
TLDR
Results of this consensus conference on endometrial cancer, together with a summary of evidence supporting each recommendation, are detailed in this article.
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
TLDR
The use of maintenance therapy with olaparib provided a substantial benefit with regard to progression‐free survival among women with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation, with a 70% lower risk of disease progression or death with olAParib than with placebo.
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
TLDR
This trial assessed rucaparib versus placebo after response to second-line or later platinum-based chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity.
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3…
TLDR
Olaparib tablet maintenance treatment provided a significant progression-free survival improvement with no detrimental effect on quality of life in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation.
Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.
TLDR
Compared with standard paclitaxel and carboplatin, addition of a third cytotoxic agent provided no benefit in PFS or OS after optimal or suboptimal cytoreduction as well as survival analyses of groups defined by size of residual disease.
...
1
2
3
4
5
...